Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Justin Taylor, MD, Morgan Coleman, MPH, Kelsey Alvarez, RN, Janine Pichardo, Filiz Sen, MD, Stephen S. Chung, MD, Raajit K. Rampal, MD PhD, Jae H. Park, MD, Eytan M. Stein, MD, Martin S. Tallman, MD, Omar I Abdel-Wahab, MD, Virginia M. Klimek, MD

Blood (2018) 132 (Supplement 1): 233.

https://doi.org/10.1182/blood-2018-99-113840

Published: 2018

Journal Articles

CD99 Regulates Normal and Malignant Stem Cell Function By Restricting Protein Translation

Stephen S. Chung, MD, Wenhuo Hu, PhD, Liang Guo, PhD, Lavanya Kannan, PhD, Ross L. Levine, MD, Christopher Y. Park, MD PhD

Blood (2017) 130 (Supplement 1): 3749.

https://doi.org/10.1182/blood.V130.Suppl_1.3749.3749

Published: 2017

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia

Blood (2016) 128 (22): 599.

https://doi.org/10.1182/blood.V128.22.599.599

Published: 2016

Journal Articles

CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function

Gaëlle H Martin, PhD, Alexis Desrichard, PhD, Stephen S. Chung, MD, Carolien Woolthuis, PhD, Wenhuo Hu, PhD, Francine E. Garrett-Bakelman, MD PhD, Jörg Hamann, PhD, Timothy Chan, MD PhD, Christopher Y. Park, MD PhD

Blood (2016) 128 (22): 1077.

https://doi.org/10.1182/blood.V128.22.1077.1077

Published: 2016

Journal Articles

An Analysis of the Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at Single Cell Resolution

Stephen S. Chung, MD, Priyanka Vijay, Diana L. Stern, Virginia M. Klimek, MD, Christopher E. Mason, PhD, Christopher Y. Park, MD PhD

Blood (2016) 128 (22): 960.

https://doi.org/10.1182/blood.V128.22.960.960

Published: 2016

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Benjamin Durham, MD PhD, Young Rock Chung, MS, Sasinya Scott, MPH, Bartlomiej Getta, MBBS,, Eunhee Kim, PhD, Alan Saven, MD, Richard M. Stone, MD, Kanti R Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Neal Rosen, MD PhD, Ross L. Levine, MD, Michael Berger, PhD, Martin S Tallman, MD, Omar Abdel-Wahab

Blood (2015) 126 (23): 449.

https://doi.org/10.1182/blood.V126.23.449.449

Published: 2015

Journal Articles

Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies

Montreh Tavakkoli, MA, Dong H. Lee, MD, Benjamin Durham, MD PhD, Stephen S. Chung, MD, Christopher Y. Park, MD, PhD

Blood (2015) 126 (23): 2749.

https://doi.org/10.1182/blood.V126.23.2749.2749

Published: 2015

Journal Articles

Analysis of Myelodysplastic Syndrome Stem Cells at Single Cell Resolution during DNA Methyltransferase Inhibitor Therapy

Stephen S. Chung, MD, Priyanka Vijay, Diana L. Stern, Deirdre O'Sullivan, Virginia M. Klimek, MD, Christopher Mason, PhD, Christopher Y. Park, MD, PhD

Blood (2015) 126 (23): 4101.

https://doi.org/10.1182/blood.V126.23.4101.4101

Published: 2015

Journal Articles

Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

Blood (2015) 126 (23): 306.

https://doi.org/10.1182/blood.V126.23.306.306

Published: 2015

Journal Articles

Mutation Profiling of Therapy-Related Myeloid Neoplasms Using Next-Generation Sequencing Demonstrates Distinct Profiles from De Novo Disease

Alan H. Shih, MDPhD, Franck Rapaport, PhD, Stephen S. Chung, MD, Emily K Dolezal, Sean Hobson, MA, Mary K Amato, Christopher Y. Park, MD PhD, Mikkael A. Sekeres, MD MS, Marcel R.M. van den Brink, MD PhD, Stephen Nimer, MD, Ross L. Levine, MD, Jaroslaw P. Maciejewski, MD PhD, Virginia M. Klimek, MD

Blood (2014) 124 (21): 4611.

https://doi.org/10.1182/blood.V124.21.4611.4611

Published: 2014

Journal Articles

CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes

Stephen S. Chung, MD, Montreh Tavakkoli, BS, Virginia M. Klimek, MD, Christopher Y. Park, MD PhD

Blood (2014) 124 (21): 3760.

https://doi.org/10.1182/blood.V124.21.3760.3760

Published: 2014

Journal Articles

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MS, Helen Won, MS, Eunhee Kim, PhD, Alan Saven, MD, Martha Wadleigh, MD, Richard M. Stone, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Mario E Lacouture, MD, Neal Rosen, MD PhD, Michael Berger, PhD, Ross L Levine, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 24.

https://doi.org/10.1182/blood.V124.21.24.24

Published: 2014

Journal Articles

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Michelle Perugini, PhD, Saumya E Samaraweera, PhD, Anna L Brown, PhD, Nik Cummings, BSc, Silke Danner, Ing Soo Tiong, MBChB, Francine E Garrett-Bakelman, MD PhD, Martin P. Carroll, MD, Michael W. Becker, MD, Stephen S. Chung, MD, Christopher Y. Park, MD PhD, Christopher E Mason, PhD, Monica L. Guzman, PhD, Ross L. Levine, MD, Ari M Melnick, MD, Luen Bik To, MBBS, PhD, Andrew H Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 69.

https://doi.org/10.1182/blood.V124.21.69.69

Published: 2014

Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 2876.

https://doi.org/10.1182/blood.V122.21.2876.2876

Published: 2013

Journal Articles

CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes

Stephen S. Chung, MD, Montreh Tavakkoli, BS, Sean M. Devlin, PhD, Christopher Y. Park, MD, PhD

Blood (2013) 122 (21): 2891.

https://doi.org/10.1182/blood.V122.21.2891.2891

Published: 2013

Journal Articles

MiR-29a Maintains Hematopoietic Stem Cell Self-Renewal and Is Required For Myeloid Leukemogenesis

Wenhuo Hu, MD, PhD, James Dooley, PhD., Stephen S. Chung, MD, Safak Yalcin, PhD, Yu Sup Shin, BSc, Bart De Strooper, MD, PhD, Adrian Liston, PhD., Christopher Y. Park, MD, PhD

Blood (2013) 122 (21): 1190.

https://doi.org/10.1182/blood.V122.21.1190.1190

Published: 2013

Journal Articles

Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia

Blood (2013) 122 (21): 2499.

https://doi.org/10.1182/blood.V122.21.2499.2499

Published: 2013

Journal Articles

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Stephen S. Chung, MD, Jae H. Park, MD, Eunhee Kim, PhD, Young Rock Chung, MSc, Wenhuo Hu, PhD, Piro Lito, MD, PhD, Julie Teruya Feldstein, MD, Raajit K. Rampal, M.D., Ph.D., Leon Telis, Minal Patel, Neal Rosen, Christopher Y. Park, M.D., Ph.D., Martin S. Tallman, MD, Omar Abdel-Wahab, MD

Blood (2013) 122 (21): 816.

https://doi.org/10.1182/blood.V122.21.816.816

Published: 2013

NARROW

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

CD99 Regulates Normal and Malignant Stem Cell Function By Restricting Protein Translation

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia

CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function

An Analysis of the Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at Single Cell Resolution

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies

Analysis of Myelodysplastic Syndrome Stem Cells at Single Cell Resolution during DNA Methyltransferase Inhibitor Therapy

Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

Mutation Profiling of Therapy-Related Myeloid Neoplasms Using Next-Generation Sequencing Demonstrates Distinct Profiles from De Novo Disease

CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes

MiR-29a Maintains Hematopoietic Stem Cell Self-Renewal and Is Required For Myeloid Leukemogenesis

Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only